Pharma BD Deal Intelligence

Pfizer Inc. / King Pharmaceuticals, Inc.

2010 · Acquisition/Merger · $3.6B · Complete

Announcement Sentiment

Strongly positive

Pfizer completed acquisition of King Pharmaceuticals on February 28, 2011, having announced the $3.6B all-cash deal in October 2010. Deal added pain franchise (Embeda, Avinza, Flector Patch) and EpiPen.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced Oct 12, 2010
Closed Feb 28, 2011
Deal value $3.6B
Deal type Acquisition/Merger
Therapeutic area Pain, allergic emergency
Indications Pain, allergic emergency
Key assets Embeda, Avinza, Flector Patch (pain portfolio); EpiPen
Mechanism Opioid analgesics + epinephrine auto-injector

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals